Evidence map›Paper›PMID 34872611›Full record

Observational studyCritical care (London, England)2021

HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients.

Antoine Meyer, Niccolò Buetti, Nadhira Houhou-Fidouh, Juliette Patrier, Moustafa Abdel-Nabey, Pierre Jaquet, Simona Presente, Tiphaine Girard, Faiza Sayagh, Stephane Ruckly and 6 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Critical care (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Systematic review with meta-analysis of active herpesvirus infections in patients with COVID-19: Old players on the new field.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Review
  19. Viral reactivations and fungal infections in nonresolving acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Antoine MeyerINSERM, IAME, University of Paris, 75006, Paris, France.
Niccolò BuettiINSERM, IAME, University of Paris, 75006, Paris, France. niccolo.buetti@gmail.com.ORCID 0000-0002-8096-1834
Nadhira Houhou-FidouhVirology Department, GH APHP.Nord, Bichat-Claude Bernard University Hospital, 75018, Paris, France.
Juliette PatrierMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Moustafa Abdel-NabeyMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Pierre JaquetMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Simona PresenteMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Tiphaine GirardMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Faiza SayaghMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Stephane RucklyINSERM, IAME, University of Paris, 75006, Paris, France.
Paul-Henri WickyMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Etienne de MontmollinINSERM, IAME, University of Paris, 75006, Paris, France.
Lila BouadmaINSERM, IAME, University of Paris, 75006, Paris, France.
Romain SonnevilleMedical and Infectious Diseases Intensive Care Unit, APHP, Bichat University Hospital, Paris, France.
Diane DescampsVirology Department, GH APHP.Nord, Université de Paris, IAME INSERM UMR1137, Bichat-Claude Bernard University Hospital, 75018, Paris, France.
Jean-Francois TimsitINSERM, IAME, University of Paris, 75006, Paris, France.
Assistance Publique – Hôpitaux de Paris · FRInserm · FRUniversité Claude Bernard Lyon 1 · FRUniversity of Geneva · CH

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung P4P4PM_194449
6 · The paper itself

Abstract

backgroundData in the literature about HSV reactivation in COVID-19 patients are scarce, and the association between HSV-1 reactivation and mortality remains to be determined. Our objectives were to evaluate the impact of Herpes simplex virus (HSV) reactivation in patients with severe SARS-CoV-2 infections primarily on mortality, and secondarily on hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) and intensive care unit-bloodstream infection (ICU-BSI).

methodsWe conducted an observational study using prospectively collected data and HSV-1 blood and respiratory samples from all critically ill COVID-19 patients in a large reference center who underwent HSV tests. Using multivariable Cox and cause-specific (cs) models, we investigated the association between HSV reactivation and mortality or healthcare-associated infections.

resultsOf the 153 COVID-19 patients admitted for ≥ 48 h from Feb-2020 to Feb-2021, 40/153 (26.1%) patients had confirmed HSV-1 reactivation (19/61 (31.1%) with HSV-positive respiratory samples, and 36/146 (24.7%) with HSV-positive blood samples. Day-60 mortality was higher in patients with HSV-1 reactivation (57.5%) versus without (33.6%, p = 0.001). After adjustment for mortality risk factors, HSV-1 reactivation was associated with an increased mortality risk (hazard risk [HR] 2.05; 95% CI 1.16-3.62; p = 0.01). HAP/VAP occurred in 67/153 (43.8%) and ICU-BSI in 42/153 (27.5%) patients. In patients with HSV-1 reactivation, multivariable cause-specific models showed an increased risk of HAP/VAP (csHR 2.38, 95% CI 1.06-5.39, p = 0.037), but not of ICU-BSI.

conclusionsHSV-1 reactivation in critically ill COVID-19 patients was associated with an increased risk of day-60 mortality and HAP/VAP.

Indexed as

COVID-19Herpesvirus 1, HumanPneumoniaCritical IllnessHumansRisk AssessmentBacteremiaCOVID-19Critically illHSVMortalityPneumonia

Identifiers

PMID34872611
PMCPMC8647503
OpenAlexW4200144025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.